Health & wellness — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 12 September 2026 and assigned it the closest of 31 fixed categories, at 83% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and why it has no browse page of its own yet.
Growth
13 measurements spanning 37 days, net +94. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 7,099–7,221 and does not start at zero.
Measurement log — every subscribers count we have recorded
Measured (UTC)
Subscribers
Change
12 Sept 2026, 19:56
7,207
+10
9 Sept 2026, 02:14
7,197
+22
3 Sept 2026, 20:42
7,175
+18
31 Aug 2026, 07:35
7,157
-3
28 Aug 2026, 13:24
7,160
+7
26 Aug 2026, 00:11
7,153
+9
22 Aug 2026, 23:26
7,144
+4
19 Aug 2026, 18:44
7,140
+8
16 Aug 2026, 18:25
7,132
+8
13 Aug 2026, 07:44
7,124
+4
9 Aug 2026, 21:51
7,120
+5
7 Aug 2026, 06:13
7,115
+2
6 Aug 2026, 08:16
7,113
first reading
Engagement
13 posts held, back to 3 July 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 13 pages of Telegram’s post history, 20 posts per page.
Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 13 posts for this entry, the most recent from 13 August 2026. An engagement rate over an empty window would be a number about nothing.
What this channel posts
Video runtime
1m 01s
Average length
1m 01s
Measured directly from 1 video with a duration reading, out of the posts we hold for this channel — not this channel’s whole posting history, only the sample this register has actually read. An exact reading to the second, taken from the post itself rather than from Telegram’s own rounded chrome, so it carries no ≈ mark.
Reaction mix
92 reactions across 10 posts, in 4 distinct kinds. The most used accounts for 68.5% of them.
Every reaction kind recorded on the sample, most used first
Reaction
Count
Share
Share, drawn
❤
63
68.5%
🔥
14
15.2%
👍
13
14.1%
😱
2
2.17%
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 11 of the 13 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 102 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 13 most recent posts we hold, published 3 July 2026 to 13 August 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
Исследование P-RAD (ASCO 2026): лучевая терапия как «активатор» иммунного ответа при N+ ТНРМЖ
Лучевая терапия давно рассматривается не только как метод локального контроля, но и как потенциальный «активатор» противоопухолевого иммунитета. Отсюда вытекает механистический вопрос: можно ли предоперационным облучением усилить иммунный ответ ещё до начала химиотерапии — и даст ли это измеримый клинический выигрыш?
Именно …
Болотина Лариса Владимировна
Заведующая отделением химиотерапии МНИОИ им. П.А. Герцена – филиала ФГБУ «НМИЦ радиологии» Минздрава России, председатель рабочей группы по разработке Клинических рекомендаций RUSSCO, член правления RUSSCO, доктор медицинских наук, профессор РАН, Москва приглашает к участию в XXX Российском онкологическом конгрессе
с международным участием
10-12 декабря 2026, Москва
Подробнее: https://w…
Уважаемые коллеги!
Приглашаем вас принять участие в анонимном опросе, посвященном актуальным трудностям коммуникации между врачом-онкологом, пациентом и его родственниками. Цель исследования – определить наиболее распространенные организационные и клинические ситуации, требующие поддержки, обучения и разработки практических инструментов коммуникации.
Пройти опрос: https://rosoncoweb.ru/surveys/communication_with_pa…
ИПП и иммунотерапия
В июле 2026 года в The Lancet Oncology был опубликован post-hoc анализ исследования PACIFIC, посвященный влиянию ингибиторов протонной помпы (ИПП) и антибиотиков на эффективность терапии дурвалумабом у пациентов с местнораспространенным НМРЛ.
В анализ были включены 660 пациентов из 713 рандомизированных: 449 получили дурвалумаб, 211 — плацебо. За 30 дней до начала рандомизации ингибиторы протонн…
ESMO GI 2026: результаты подгруппового анализа исследования GALAXY
В настоящее время циркулирующая опухолевая ДНК (цоДНК) стала перспективным биомаркером для определения минимальной остаточной болезни (MRD) и прогнозирования риска рецидива. В июле 2026 года на ESMO GI представлены результаты подгруппового анализа исследования GALAXY, в котором оценивались прогностическая значимость цоДНК и связь MRD-статуса с безрец…
В июне 2026 г. в Копенгагене прошел еще один ежегодный конгресс - ESMO GYN, посвященный лечению онкогинекологических заболеваний.
Вот самые интересные моменты:
1️⃣ Иммунотерапия при метастатическом/рецидивируюшем dMMR раке эндометрия - излечивающая опция для трети пациентов.
❗️При 4-летнем наблюдении в исследовании RUBY part 1 (1 линия - химиотерапия+достарлимаб) для dMMR РЭ полный ответ достигнут у 32% (17/53), 5…
Верите ли Вы в успех RAS-ингибиторов в лечении рака поджелудочной железы?
1. Да, через несколько лет я вижу комбинации с ними в 1 линии71%
2. Да, но во 2+ линиях19%
3. Нет, вероятнее всего, они провалятся в РКИ III фаз12%
The shares total 102%, above 100: this poll accepts more than one answer per voter. No per-option vote count is published, so the number of voters who chose each option is not derivable and is not shown.
ESMO GI 2026: Золдонрасиб (RMC-9805) в лечении метастатического рака поджелудочной железы
Мутации гена KRAS встречаются примерно в 80-90% случаев РПЖ. Наиболее частые их виды – G12D и G12V (около 70%).
С учетом крайне неблагоприятного прогноза и биологии большая надежда в лечении РПЖ возлагается на RAS-ингибиторы.
На ESMO GI представлен еще один KRAS-ингибитор – золдонрасиб, нацеленный на мутацию G12D. Ниже результ…
Тарлатамаб при мелкоклеточном раке легкого: результаты анализа пациентов с метастазами в головной мозг (ASCO 2026) 📌
Тарлатамаб - биспецифическое антитело, которое связывает белок дельта-подобный лиганд 3 (DLL3), экспрессирующийся на клетках МРЛ, и рецептор CD3 на Т-лимфоцитах. Благодаря этому собственные Т-клетки пациента активируются, распознают и уничтожают опухолевые клетки.
В рандомизированном исследовании III…
Подкасты
Глубокоуважаемые коллеги!
Российское общество клинической онкологии открывает новый раздел на сайте RosOncoWeb.ru – ПОДКАСТЫ.
Несмотря на развитие визуального искусства, подкасты продолжают набирать популярность и привлекать все большую аудиторию. Вам не нужно откладывать свои дела ради онлайн-трансляции интересного вебинара. Вы можете включить запись, когда и где вам будет удобно. Экономия времени и возм…
📌 PROTEUS: периоперационный апалутамид+АДТ при локализованном РПЖ высокого риска
Рандомизированное двойное слепое плацебо-контролируемое исследование III фазы.
Оценка периоперационной интенсификации апалутамидом у пациентов с впервые диагностированным локализованным/местнораспространенным РПЖ высокого риска.
💡 Дизайн
Пациенты рандомизировались 1:1 на: АДТ+апалутамид vs АДТ+плацебо (6 мес. до и 6 мес. после РПЭ с т…
👍3
Showing the 12 most recent of 13 posts we hold for @russco1. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Polls
The 2 polls we hold for this entry, as Telegram rendered them when we read the post. A poll’s figures keep moving after that, so each one is dated.
Верите ли Вы в успех RAS-ингибиторов в лечении рака поджелудочной железы?
1. Да, через несколько лет я вижу комбинации с ними в 1 линии71%
2. Да, но во 2+ линиях19%
3. Нет, вероятнее всего, они провалятся в РКИ III фаз12%
The shares total 102%, above 100: this poll accepts more than one answer per voter. No per-option vote count is published, so the number of voters who chose each option is not derivable and is not shown.
Percentages only — there are no per-option vote counts here, because Telegram publishes none. The public post preview gives each option’s share and a single voter total, and nothing else. Multiplying one by the other would produce a per-option tally that looks measured and is not: the shares are rounded to whole numbers before we ever see them. We print what was published and leave the column that does not exist empty.
The shares need not add up to 100. Rounding alone puts many polls at 99 or 101. A poll that allows more than one answer per voter runs well past 100 by design, and several here do. The bars are drawn against a fixed 100% track at each option’s own percentage rather than normalised to the total, so a poll that exceeds it shows that it does instead of being quietly rescaled.
Read from the 13 most recent posts we hold, published 3 July 2026 to 13 August 2026. Telegram labels each poll by kind — an anonymous poll, a quiz, a closed set of final results — and that label is reproduced rather than paraphrased.
Forward network
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Mentions
Named by 3 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.
Named by
Channels on the register whose posts name this channel's handle.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
Appears in Telegram’s recommendations for other channels
The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.
Онкология простыми словами @oncolya · 27,282 Telegram ranks this channel #3 of 98 here — alongside 97 others — read 11 September 2026
ГЛАВНЫЙ ОНКОЛОГ Андрей КАПРИН @ADKaprin · 32,230 Telegram ranks this channel #5 of 98 here — alongside 97 others — read 7 September 2026
Dr.Ivashkov @drivashkov · 34,458 Telegram ranks this channel #28 of 89 here — alongside 88 others — read 6 September 2026
ЗдравКонтроль @martynovevgueni · 218,393 Telegram ranks this channel #73 of 96 here — alongside 95 others — read 11 August 2026
Аккредитация врачей | Ординатура @credit_med · 23,124 Telegram ranks this channel #93 of 96 here — alongside 95 others — read 19 September 2026
Поясни за мед @poyasni_za_med · 22,289 Telegram ranks this channel #96 of 97 here — alongside 96 others — read 21 September 2026
This channel appears in 6 seed channels' Telegram-generated recommendation lists in total. Each is Telegram’s list for THAT channel, not this one — see how this is measured.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 12 September 2026 — this
entry's latest reading, not the date you are reading this.
“RUSSCO - Российское общество клинической онкологии” (@russco1), 7,207 subscribers as measured 12 September 2026. Telegram Register, tgregister.com/channel/russco1.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.